NCT07203482Recruiting
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
A Single-center Observational Study of Clinical Outcomes of Clinically Localized Prostate Cancer Undergoing HIFU Therapy
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, oncologic outcomes and urinary/sexual function, and identify predictors of complications, oncological control and functional outcomes after Hhigh-intensity focused ultrasound (HIFU) ablation of prostate cancer with the intent to guide further research and improve patient care. We will include subjects who will have a HIFU procedure performed from all Sub-Investigators included in the study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 23 Sept 2025
- Start date
- 16 May 2024
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- NYU Langone Health
- Diseases
- Prostate cancer
- NCT number
- NCT07203482
What you commit to
- Study type: Observational
- Planned participants: 300
- From 16 May 2024 to the primary completion date, 31 Dec 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients that are not diagnosed with prostate cancer.
- Patients that are diagnosed with clinically localized prostate cancer, but select other tratment options as their desired treatment.
Other
- Patients that are not willing or are not able to give consent.
Who the study is looking for
- Males, ages 40-95
- Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy
- Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) that select focal HIFU prostate ablation as their treatment option will be offered inclusion into this prospective data collection research database.
- Patients who have early (Gleason 6 or 7), low grade cancer that is confined to the prostate.
- Willing and able to provide consent.
Age in the registry: 40 years to 95 years · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Health - Cobble Hill Coordinator of this site? Confirm its status | Brooklyn | United States | Recruiting |
| NYU Langone Health - Tisch Hospital Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.